Postmarketing Study for Determine Performance of the SIGMA HP® PARTIAL KNEE SYSTEM

Recruiting

You are on the General Public view
  • Source

    -
    Public Title Postmarketing Study for Determine Performance of the SIGMA HP® PARTIAL KNEE SYSTEM
    Acronym Sorry, not currently available
    Source of Record URL http://clinicaltrials.gov/show/NCT01529099
  • Trial

    -
    Health Condition(s) or Problem Osteoarthritis; Post-traumatic Arthritis; Gout; Pseudo-gout
    Lay Summary This is a postmarketing study to assess the overall performance and survivorship of the SIGMA HP® PARTIAL KNEE SYSTEM. (from ClinicalTrials.gov)
    Who can enter the trial Inclusion Criteria: - Male or female subjects, aged at least 21 years. - Subjects who are able to give voluntary, written informed consent to participate in this clinical investigation and from whom consent has been obtained. - Subjects, who, in the opinion of the Clinical Investigator, are able to understand this clinical investigation, co-operate with the investigational procedures and are willing to return to the hospital for all the required post-operative follow-ups. - Subject has non-inflammatory degenerative joint disease (NIDJD), including: OA, posttraumatic arthritis, avascular necrosis and chondrocalcinosis. - Subject has a functional stable knee. - Subject, in the opinion of the Investigator, is suitable for either a single or bicompartmental knee replacement. - Subject meets the following selected radiographic parameters: - X-ray evaluation confirms the presence of NIDJD - Disease location: 1 to 2 compartments, maximum. Disease can be present in the patellofemoral compartment, the medial tibiofemoral compartment, lateral tibiofemoral compartments alone or in any two compartments. - Disease severity: Kellgren and Lawrence44 Grade II or greater for all compartments replaced. Exclusion Criteria: - Subjects who, in the opinion of the Clinical Investigator, have an existing condition that would compromise their participation and follow-up in this clinical investigation. - Women who are pregnant. - Subjects who are known drug or alcohol abusers or with psychological disorders that could affect follow-up care or treatment outcomes. - Subjects who have participated in a clinical investigation with an investigational product in the last 3 months. - Subjects who are currently involved in any injury litigation claims. - Multiple joint involvement that will compromise rehabilitation (for example: advanced hip, ankle or spine disease). - Known to be a prisoner, mentally incompetent, an alcohol / drug abuser, involved in medical-legal case or worker's compensation - Previous knee arthroplasty (any type) in any one of the three compartments of the knee. - Requires more than a lateral soft tissue release or an anterior cruciate ligament reconstruction. - Uncorrectable anatomical tibio-femoral angle. - Bone deficiency requiring structural bone grafts to support the implants. - Previous patellectomy. - For Subjects indicated for a PFA, Subject has uncorrected patella baja (Caton-Deschamps ratio less than or equal to 0.6). - Tri-compartmental disease process (patella-femoral, medial tibio-femoral and lateral tibio-femoral). - Active bacterial infection that may spread to other areas of the body (e.g., osteomyelitis, pyogenic infection of knee joint, urinary tract infection, etc.). - Significant neurological or musculoskeletal deformity or a disease that may affect gait or weight bearing, (e.g., muscular dystrophy, multiple sclerosis, amputation). - Known allergy to implant materials.
    Who cannot enter the trial Inclusion Criteria: - Male or female subjects, aged at least 21 years. - Subjects who are able to give voluntary, written informed consent to participate in this clinical investigation and from whom consent has been obtained. - Subjects, who, in the opinion of the Clinical Investigator, are able to understand this clinical investigation, co-operate with the investigational procedures and are willing to return to the hospital for all the required post-operative follow-ups. - Subject has non-inflammatory degenerative joint disease (NIDJD), including: OA, posttraumatic arthritis, avascular necrosis and chondrocalcinosis. - Subject has a functional stable knee. - Subject, in the opinion of the Investigator, is suitable for either a single or bicompartmental knee replacement. - Subject meets the following selected radiographic parameters: - X-ray evaluation confirms the presence of NIDJD - Disease location: 1 to 2 compartments, maximum. Disease can be present in the patellofemoral compartment, the medial tibiofemoral compartment, lateral tibiofemoral compartments alone or in any two compartments. - Disease severity: Kellgren and Lawrence44 Grade II or greater for all compartments replaced. Exclusion Criteria: - Subjects who, in the opinion of the Clinical Investigator, have an existing condition that would compromise their participation and follow-up in this clinical investigation. - Women who are pregnant. - Subjects who are known drug or alcohol abusers or with psychological disorders that could affect follow-up care or treatment outcomes. - Subjects who have participated in a clinical investigation with an investigational product in the last 3 months. - Subjects who are currently involved in any injury litigation claims. - Multiple joint involvement that will compromise rehabilitation (for example: advanced hip, ankle or spine disease). - Known to be a prisoner, mentally incompetent, an alcohol / drug abuser, involved in medical-legal case or worker's compensation - Previous knee arthroplasty (any type) in any one of the three compartments of the knee. - Requires more than a lateral soft tissue release or an anterior cruciate ligament reconstruction. - Uncorrectable anatomical tibio-femoral angle. - Bone deficiency requiring structural bone grafts to support the implants. - Previous patellectomy. - For Subjects indicated for a PFA, Subject has uncorrected patella baja (Caton-Deschamps ratio less than or equal to 0.6). - Tri-compartmental disease process (patella-femoral, medial tibio-femoral and lateral tibio-femoral). - Active bacterial infection that may spread to other areas of the body (e.g., osteomyelitis, pyogenic infection of knee joint, urinary tract infection, etc.). - Significant neurological or musculoskeletal deformity or a disease that may affect gait or weight bearing, (e.g., muscular dystrophy, multiple sclerosis, amputation). - Known allergy to implant materials.
    What will happen Device; SIGMA HP PARTIAL KNEE; SIGMA HP PARTIAL KNEE; Sigma HP Partial Knee; Sigma HP Partial Knee Femoral component; Sigma HP Partial Knee Tibial component; Sigma HP Partial Knee Tibial insert component; Sigma Patellae; Sigma HP Partial Knee Trochlear component
    Primary aim Survivorship (revision)
    Secondary Aim Survivorship; 1, 2, 5 and 10 years; Yes; Survival analyses at each post-operative assessment.; Knee Society Score; 1, 2, 5 and 10 years; No; Mean change from baseline (pre-op) to each post-operative assessment; KOOS; 1, 2, 5 and 10 years; No; Mean change from baseline (pre-op) to each post-operative assessment.; HAAS; 1, 2, 5 and 10 years; No; Mean change from baseline (pre-op) to each post-operative assessment.; Kujala Score; 1, 2, 5 and 10 years; No; Mean change from baseline (pre-op) to each post-operative assessment.; Oxford Knee Score; 1, 2, 5 and 10 years; No; Mean change from baseline (pre-op) to each post-operative assessment.; EQ-5D; 1, 2, 5 and 10 years; No; Mean change from baseline (pre-op) to each post-operative assessment.; Radiographic Analysis; 1, 2, 5 and 10 years; Yes; Change from 6 week post-operative assessment at all post-operative timepoints to identify the number of implants that are 'at risk'.
    Participant Information Sheet Sorry, not currently available
    Website Sorry, not currently available
    Recruitment Status Recruiting
    Nation England
    Location Harrogate, York
  • Contact

    -
    Contact for Public Queries Sue Kemp, Ph.D +44113 3877804 skemp1@its.jnj.com Mr A Gibbon, BSc MBBS FRCS(Orth) Principal Investigator Clifton Park NHS Treatment Centre
    Contact for Scientific Queries W Herzberg, Dr. med.; Principal Investigator; S Preiss; Principal Investigator; A Gibbon, BSc MBBS FRCS(Orth); Principal Investigator
Please note:
  1. The UKCTG information is designed to inform you of existing trials. If you wish to join a specific trial, you must discuss this with your own doctor who may decide to get in touch with the contact listed.
  2. The UKCTG is not responsible for the quality of the data displayed in the Gateway but can contact the data providers. Please contact us if you have any query regarding the quality of trial records.